

# **TELEMEDICINE IN CHRONIC HEART DISEASE IN HONG KONG- CARE FROM A DISTANCE?**

***DR KATHERINE FAN***

**CONSULTANT CARDIOLOGIST  
CARDIAC MEDICAL UNIT  
GRANTHAM HOSPITAL**

# THE CLOUD REVOLUTION

Uber, the world's largest taxi company, owns no vehicles. Facebook, the world's most popular media owner, creates no content. Alibaba, the most valuable retailer, has no inventory. And Airbnb, the world's largest accommodation provider, owns no real estate. Something interesting is happening.

- Tom Goodwin

# WHAT IF PATIENTS DO NOT NEED TO COME/ STAY IN HOSPITAL?



# NEW HEALTH CARE ACCESS IN NEW AND NON-TRADITIONAL VENUES

Target



- Convenient care at a lower price than traditional healthcare delivery systems
- Robust consumer mobile health applications that can be easily integrated with existing health solutions
- Enable a cultural shift in healthcare delivery in a convenient and efficient service model

**DISRUPTION OF TRADITIONAL  
HEALTH CARE HAS  
INTRODUCED NEW  
MECHANISM FOR THE  
MEDICAL CONSUMER TO  
ACCESS HEALTHCARE USING  
DIGITAL TOOLS...**

# TELEMONITORING IN HK (NGO)




「平安手機®」服務  
活躍好動銀齡人士的  
貼身支援伙伴



Senior Citizen Home Safety Association



# TELEMONITORING IN HK (TELECOMMUNICATIONS)



# INNOVATIVE INSURANCE CONCEPT



- Fitness trackers are linked online through mobile apps
- Allows individuals to monitor activity progress against set goals
- Target reached will result in discounts on their insurance premiums



# TELEMEDICINE

- Defined as delivery of healthcare or information at a distance via technology, and includes services such as assessment, monitoring, communications, disease prevention, and education

## **BOTH PROCESS & OUTCOME OF CARE**

- Providing education- (improve self management)
- Enabling information transfer (telemonitoring)
- Facilitating contact with health professionals (telephone support and follow-up)
- Improving electronic records

## **TWO TYPES:**

- Provision of remote clinical services, via **real-time two-way communication** between the patient and the healthcare provider, using electronic audio and visual means
- Store-and-forward transmission of data (asynchronously)
  - **Monitoring applications** can be entirely automatic or having required the patient to do something

# DEVICES USED IN CARDIAC REMOTE MONITORING



## Care Delivery Innovations:

Invasive Implants



Non-invasive Sensors

# SCHEMA OF CARDIAC TELEMONITORING




Clinician programs/updates monitor based on patient's condition.



Patient completes vital signs collection and responds to symptom management questions.



HomMed Monitor securely transfers medical data over network.



Clinician reviews patient assessment data and updates care plan and acts on patient events.



Physician remotely views on smartphone the patient updates and changes in condition.



Physician updates the recommended care plan to patient and clinical oversight team.

# Remote Monitoring Using CIEDs

CIEDs with Remote Monitoring capability

Remote Monitoring transmitter

Remote Monitoring system website



Devices send information via wireless radio frequency at scheduled time



Encrypted information upload through household telephone lines



Treatment, detection & record

Encrypt the Received information

Authorized personnel access the information by logging into the system with PIN codes

\*CIEDS= Cardiac Implantable Electrical Devices

# Personnel access the information by logging into the system with Authorized PIN codes

Report in Remote Monitoring System

FastPath® Summary Aug 26, 2011, 11:14 am (HKT)

---

**1 Alert**

Congestion Exceeded Trigger

**Note**


**Current Brady Parameters**

Mode: **DDD**  
 Base Rate: 70 bpm  
 Max Track Rate: 130 bpm  
 Paced/Sensed AV Delay: 160/110 ms  
 A/RV/LV Pulse Amp: 1.75/2.0/2.125 V  
 A/RV/LV Pulse Width: 0.4/0.4/0.4 ms

---

**Battery Information**

Longevity: **6.0-6.3 yrs**



~ERI

Last Max Charge: 9.4 sec (Aug 5, 2011)

Battery Current: 16 uA  
 Remaining Capacity to ERI: 82 %

**Current Tachy Parameters**

Zone Configuration: 2 Zones

VT	VF
166 bpm	181 bpm
ATPx3, 15.0J, 30.0J, 40.0Jx2	ATPx1, 32.0J, 40.0J, 40.0Jx4

---

**Test Results** (Last Session: Aug 3, 2011)

**A Automatic**

	<u>Atrium</u>	<u>R. Ventricle</u>	<u>L. Ventricle</u>
<b>Capture</b>	Today: <b>0.75 V</b> <b>A</b> Jul 1, 2011: 0.75 V	Today: <b>0.625 V</b> <b>A</b> Jul 8, 2011: 0.5 V	Today: <b>1.125 V</b> <b>A</b> Jul 8, 2011: 1.125 V
<b>Sense</b>	Today: <b>1.2 mV</b> <b>A</b> Jul 8, 2011: 3.5 mV	Today: <b>6.3 mV (RV Bi)</b> <b>A</b> Jul 8, 2011: 8.0 mV (RV Bi)	
<b>Lead Impedance</b>	Today: <b>350 Ω</b> <b>A</b> Jul 8, 2011: 360 Ω	Today: <b>400 Ω</b> <b>A</b> Jul 8, 2011: 440 Ω	Today: <b>950 Ω</b> <b>A</b> Jul 8, 2011: 940 Ω
<b>High-Voltage Lead Impedance</b>	Today: <b>37 Ω</b> <b>A</b> Jul 8, 2011: 43 Ω		

**VT/VF Episodes**

New Episodes: 0

VT	VF
0	0

SVT Episodes: 0

---


**Diagnostics**

AP: 98 %      BP: >99 %  
 Mode Switch: 0 %

# REMOTE MONITORING

## TRANSMISSION OF PRE—SET ALERTS: VT WITH APPROPRIATE SHOCKS


- 🚨 68 yrs man with DCM/ NSVT-CRT-D implanted as primary prevention
- 🚨 Stable condition after ICD shock -did not need to attend ER; patient reassured



Detection of  
Ventricular  
Tachycardia

# Initial Transmission Overview


Review the transmission steps. Click to view the monitor animations.



Unbox



Locate



Connect



Boot up



Search for signal



Press Accept



Pick up Reader



Position Reader



Interrogate



Replace Reader



Transmit



Complete




Ready

# DEVICE DATA IS CRITICAL FOR PATIENT CARE



System & health status



- Device & lead status
- Arrhythmia episodes (AT/AF)
- Delivered therapies
- AT/AF burden
- Heart rate variability
- % Pacing
- Fluid status
- Activity

**Predictive diagnostics for HF hospitalization in the next 30 days<sup>4</sup>**

<sup>4</sup> Whellen DJ., et. al. *J Am Coll Cardiol* 2010;55:1803-10.



# REDUCE HEALTHCARE UTILIZATION



Up to **1 in 4** CRT-D/ICD device patients may visit the Emergency Room<sup>1</sup>

Baseline

**35%**<sup>2</sup> potential reduction in ER visits

Remote Monitoring



Up to **1 in 2** CRT-D/ICD device patients may require a hospitalization<sup>1</sup>

**20%**<sup>3</sup> potential reduction in all-cause 3y rehospitalization

**18%**<sup>1</sup> potential reduction in hospital length of stay

# SIMPLIFIES ROUTINE FOLLOW-UP



Routine in-office visits may be replaced by remote visits resulting in **45% fewer<sup>1</sup>** in-office visits

**58% less time<sup>2</sup>** for remote vs. in-office follow-up

Remote monitoring **improves patient compliance<sup>1</sup>** to follow-up

<sup>1</sup> Varma N. *Am Heart J.* 2007;154:1029-1034. <sup>2</sup> Cronin EM, et al. *Heart Rhythm.* 2012;9:1947-1951.

# Remote Monitoring “Big Data”

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY  
© 2015 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION  
PUBLISHED BY ELSEVIER INC.

VOL. 65, NO. 24, 2015  
ISSN 0735-1097/\$36.00  
<http://dx.doi.org/10.1016/j.jacc.2015.04.033>

## The Relationship Between Level of Adherence to Automatic Wireless Remote Monitoring and Survival in Pacemaker and Defibrillator Patients



Niraj Varma, MD, PhD,\* Jonathan P. Piccini, MD, MHSc,† Jeffery Snell, BA,‡ Avi Fischer, MD,‡ Nirav Dalal, MS,‡ Suneet Mittal, MD§

**CONCLUSIONS** RM is associated with improved survival, irrespective of device type (including PMs), but demonstrates a graded relationship with the level of adherence. The results support the increased application of RM to improve patient outcomes. (J Am Coll Cardiol 2015;65:2601-10) © 2015 by the American College of Cardiology Foundation.


# Patient Adherence to RM

- “Big data” to assess
  - RM is associated with improved survival
  - Type of cardiac device
  - Degree of use
- N=269,471 consecutive pts implanted with automatic RM capable devices between 2008-2011
  - Mean age  $71 \pm 13.5$  yrs; 64.8% male
  - Mean FU  $2.9 \pm 1$  yrs

RM adherence per patient was defined as the proportion of total follow-up weeks having at least 1 status transmission or percentage of time in RM (%TRM)

53% patients never used RM


Dichotomization by a 75% use value divided RM into relatively balanced populations



# Survival in all Patients (PPM, ICD, CRT)

Survival was greater in patients in all device types

Patient Survival According to Level of Remote Monitoring Utilization: All Devices



**Patients at Risk**


	0	1	2	3	4	5
High %TRM	67,920	66,096	60,519	29,812	7,726	533
Low %TRM	59,786	57,221	52,473	30,715	10,236	1,042
RM None	141,765	129,137	115,230	62,720	18,032	1,735

**Cox Survival**

High %TRM vs RM None	HR: 2.10 (2.04-2.16) p <0.001
Low %TRM vs RM None	HR: 1.58 (1.54-1.62) p <0.001
High %TRM vs Low %TRM	HR: 1.32 (1.27-1.36) p <0.001

Mean Follow-Up: 2.87 (1.03) Years

# OUTCOMES WERE SUPERIOR IN HIGH %TRM AND LOW %TRM FOR ALL DEVICE TYPES



The degree of adherence correlates with the magnitude of survival gain, suggesting a gradient of effect

Critical impact of adherence: for maximal benefit of RM:

Earlier activation and then maintenance of consistent transmissions were associated with best outcomes

**TELEMONITORING FOR  
HEART FAILURE  
DISEASE MANAGEMENT  
IN HONG KONG**

# HEART FAILURE – A GROWING GLOBAL CONCERN

## Prevalence and Incidence

Overall 2.1% prevalence: 5.1M heart failure patients in 2010<sup>1</sup>

825,000 people  $\geq$  45 years of age are newly diagnosed each year with HF.<sup>1</sup>

15 M heart failure patients in the European countries<sup>2</sup>

- Overall 2-3% prevalence<sup>2</sup>

## Mortality

For AHA/ACC stage C/D patients diagnosed with HF:

- 30% will die in the first year.<sup>3-5</sup>
- 60% will die within 5 years.<sup>5</sup>

**HF prevalence in the US is projected to increase 46% from 2012 to 2030, resulting in > 8M people  $\geq$  18 years of age with HF.<sup>6</sup>**

1. AHA 2014 Statistics at a Glance, 2014
2. The European Society of Cardiology, ESC HF Guideline, 2008
3. Curtis et al, Arch Intern Med, 2008.
4. Roger et al. JAMA, 2004.
5. Cowie et al, EHJ, 2002.
6. Heidenreich PA et al. Circ Heart Failure 2013.



# HEART FAILURE IS ASSOCIATED WITH HIGH HOSPITALIZATION AND READMISSION RATES

In 2010, there were 1 million hospitalizations in the US with HF as the principal diagnosis.<sup>1</sup>

- Hospitalization rate did not change significantly from 2000.<sup>1</sup>


## Average length of hospital stay

- Approximately 5 days (US)<sup>2</sup>
- 11 days (Europe)<sup>3</sup>

## HF is associated with high readmission rates:

- ~25% all-cause readmission within 30 days<sup>4</sup> and ~50% within 6 months<sup>5</sup>

Average length of stay, heart failure, international, 1997–2007




Note: some countries may include deaths and discharges as well as same-day separations.

1. CDC NCHS National Hospital Discharge Survey, 2000-2010
2. Yancy et al. JACC, 2006.
3. Cleland et al. EuroHeart, 2003.
4. Krumholz HM, et al. Circ Cardiovas Qual Outcomes 2009.
5. Wexler DJ, et al. Am Heart J 2001.

Graph from [www.health.org.uk](http://www.health.org.uk). Bridging the gap: Heart Failure, 2010.  
Data from Organization for Economic Cooperation and Development, 2009.

# WORSENING HEART FAILURE LEADING TO HF-RELATED HOSPITALIZATIONS CONTRIBUTES TO DISEASE PROGRESSION

With each subsequent HF-related admission, the patient leaves the hospital with a further decrease in cardiac function.



Graph adapted from: Gheorghiade MD, et al. Am J. Cardiol. 2005


# CURRENT HF MANAGEMENT IS INADEQUATE FOR IDENTIFYING AND MANAGING CONGESTION LEADING TO DECOMPENSATION

Identifying congestion early will lead to early treatment, prevent hospitalizations and slow the progression of HF.

90% of HF hospitalizations present with symptoms of pulmonary congestion.<sup>1,2</sup>

Post hoc analysis of 463 acute decompensated HF patients from DOSE-HF and CARRESS-HF trials showed:

- 40% of patients are discharged with moderate to severe congestion.<sup>3</sup>
- Of patients decongested at discharge, 41% had severe or partial re-congestion by 60 days.<sup>3</sup>




1. Adams KF, et al. Am Heart J. 2005

2. Krum H and Abraham WT. Lancet 2009


3. Lala A, et al. JCF 2013

# LOCAL ACUTE HF ADMISSIONS DATA

## Acute HF admission in QMH



## Proportion of Readmission



In 2013, there were **3,509 acute admissions** (out of total 23,085 admissions, i.e. **15.2%**), i.e., **10 HF admissions/day**, and the means **LOS: 4.8 days** in QMH, **estimated total cost in QMH = HKD\$72,931,056** (3,509 admission x 4.8 days x HKD\$4,330)

# REMOTE MONITORING VS REMOTE DISEASE MANAGEMENT


Paradigm shift

Access to information in a more timely fashion allowing a more pro-active approach

Can we use devices as disease management tools?


- Can we provide better heart failure care?
  - *Can HF hospitalization be prevented by remote monitoring?*

# WORKFLOW AND PATHWAY OF HOME MONITORING FOR HEART FAILURE PATIENTS WITH IMPLANTABLE DEVICES



# CIEDS REMOTE MONITORING IN GH

## CIEDs Remote monitoring



- From 2010-2015
- 128 patients implanted with RM-capable devices joined RM program in GH
- Total 3495 transmissions (average 27.3 /pt)
- 154 episodes requiring interventions = 5.8% of total transmissions


# CONCEPTS OF INTRATHORACIC IMPEDANCE CORRELATING WITH HEMODYNAMIC STATUS



Drier lungs means the transthoracic impedance is higher



Better




Wetter lungs means the transthoracic impedance is lower




Worse




# INTRATHORACIC IMPEDANCE: MIDHEFT



# INTRA-THORACIC IMPEDANCE & FLUID STATUS MONITORING




# DEVICE CONGESTION MONITORING



42 yrs old lady with CCTGA  
 VSD and subvalvular PS with previous surgeries  
 SSS with sinus arrest/ VT and CHF- CRT-D implanted 12/ 2010

**CorVue™ Congestion Monitoring** Aug 3, 2011, 9:06 am (HKT)


<b>Patient &amp; Physician</b> Patient Name Birth Date Device Implant Date Implant Physician Follow-up Physician	<b>Congestion Monitoring Alert</b> No Congestion Monitoring Alert since last interrogation	<b>Congestion Monitoring Parameters</b> Congestion Monitoring <b>On</b> Congestion Trigger <b>10 days</b> Congestion Monitoring Alert <b>On</b> Patient Notifier <b>Off</b>
---	---	---



No connection with RM

**Congestion Details**

No Congestion Episodes recorded



Admission on Apr

Admission on May

Admission on Jun

Admission on Jul

IABP insertion on Jul 14

# Limitations of Device-Based Intrathoracic Impedance

## False positives

Impedance can change as a result of:

- Prolonged scar tissue at implant site
- Prolonged healing of the device pocket
- Disruption of the electrode-tissue interface secondary to lead dislodgement
- Infection affecting device pocket or electrodes
- Pericardial effusion
- Pneumonia
- Lead/electrode malfunctions
- Other unexplained changes


**A GLIMPSE  
INTO THE  
FUTURE...**

# Clinical tools to manage Heart Failure

There are many signs and symptoms of HF decompensation


- *Atrial Fibrillation*
- *Dyspnea*
- *Orthopnea*
- *Exercise Intolerance*
- *Increased Heart Rate*
- *Pulmonary Edema*

Early warning with clinical data can lead to earlier intervention






# INCREASES IN PRESSURE START THE CYCLE OF WORSENING HEART FAILURE




# CARDIOMEMS™ PA SENSOR TECHNOLOGY



The sensor is no larger than the size of a US dime

The sensor is a hermetically sealed capsule containing an inductor coil and pressure-sensitive capacitor.




The inductor coil and pressure-sensitive capacitor create a resonant circuit at a specific frequency. The blood pressure affects the resonant frequency, so that when the blood pressure changes, the resonant frequency changes. The external measurement system wirelessly tracks the resonant frequency and uses this to determine the pressure in the pulmonary artery.








**PATIENT TRANSMISSION**





**SECURE WEBSITE**



**CLINICIAN REVIEW**




# PULMONARY ARTERY PRESSURE DATABASE




Reading	
Systolic:	24
Mean:	19
Diastolic:	16
Heart Rate:	81

# CHAMPION CLINICAL TRIAL

Patients with moderate NYHA class III HF for at least 3 months, irrespective of LVEF and a HF hospitalization within the past 12 months were included in the study.




# PA PRESSURE-GUIDED THERAPY REDUCES HF HOSPITALIZATIONS



Patients managed with PA pressure data had **significantly fewer HF hospitalizations** as compared to the control group.


# CHAMPION CLINICAL TRIAL: HF MEDS CAN BE MORE EFFECTIVELY TITRATED WITH PULMONARY ARTERY (PA) PRESSURE INFORMATION



Compared to the control group, patients managed with PA pressures had significantly more total medication changes, resulting in < 1 incremental medication change/month.



# PA PRESSURE-GUIDED THERAPY REDUCES HF HOSPITALIZATIONS




# at Risk	0	90	180	270	360	450	540	630	720	810	900
Control	280	267	252	215	179	137	105	67	25	10	0
Treatment	270	262	244	210	169	131	108	82	29	5	1

- FDA approved for class III HF in May 2014
  - Success of trial relied on:
    - Effective processing of large data
    - Heart failure RN's to monitor trends
    - Oversight by HF physicians adept at interpreting hemodynamics
- Is clinical practice equipped?

Remote monitoring technologies need to be coupled with an **effective delivery system**

# REMOTE MONITORING FOR HF PATIENTS

## A DYNAMIC CONDITION WHERE RETRIEVED DATA DRIVE TREATMENT



# HEART FAILURE REMOTE MONITORING IN ASIA

## OUR EXPECTATIONS

### Improve health outcomes

- Improve QoL by offering more autonomy to patients
- Closer monitoring and more rapid dissemination of clinical data allow more informed and timelier treatment decisions

### Reduce costs

- Reduction of unnecessary hospitalizations and physicians visits
- Patients become more self responsible and thus reduces home care expenditures
- Telemedicine reduces costs in traditional data collection, recording and communications

### Fully accepted by patients

- Supposed to empower patient and generate high motivation for active participation in treatment process



# HEART FAILURE REMOTE MONITORING APPLICABILITY IN ASIA PACIFIC?

## Devices Implantation rates and FU methods

- PM ranges from 31/million in China to 565/million in Australia 2009
- ICD ranges from 1/million China and 160/million in Australia
- FU methods:
  - Follow international guidelines/recommendations eg Hong Kong , Singapore, Japan
  - Erratic FU pattern eg China/ India- patients carry their own records to see their doctors

## Multifactorial

- Difference in disease patterns
- Regional guidelines for device implantation
- Patient acceptance
- Cost

## Government Policy such as healthcare, reimbursement, telecommunication

## Technology

- Landline communication can be sparse in some countries
- Wireless communication is now widely available in Asia-Pacific region

# **CLINICAL EFFICIENCIES AND WORK-FLOW – CALL FOR DISRUPTIVE INNOVATION?**

## **WORK-FLOW CHANGES AND CHALLENGES**

**Demands on adjustment to  
different workflow patterns and  
mindsets**

**Dedicated trained allied  
professional who maintain early  
reaction ability and reported to  
responsible physicians**

**Resources needed to operate such  
a “virtual clinic” including  
reimbursement may not be  
universally available**

### **Data management**

- Best with interface with electronic medical records within one database

## **CLINICAL EFFICIENCIES**

**Greater reduction of routine non-  
actionable in-person evaluations**

**Actionable alert notification  
quickly acted upon**

**Patient engagement is  
emphasized**

- Maybe included in the loop for access to results and recommendation

### **Improved patient care**

- Expanded framework for multidisciplinary communication and collaboration eg EP and Heart Failure physicians

# MOVING CARE OUTSIDE OUR DOORS: COMMUNITY-BASED HEART DISEASE MANAGEMENT?

Yes but....

Remember goal of health system is to improve population health and to be responsive to the population's needs and demands


- Acceptance essential through effective communication and education

**The standard set has to overcome political, commercial, technical and cultural barriers**

- Countries and companies working together
- a unified open standard not just in name but in spirit

**3 important rules:**

- Mutual interests
- Open standards
- Fair markets



## 病人醫護一線牽 監察病情更全面



「你好，現在我將會為你的心臟起搏器進行檢查。」

相信植入了心臟儀器，包括起搏器、除顫器、雙室同步起搏器及雙室同步除顫器的病人到診所覆診時，都不會對這句說話感到陌生。隨著時代進步，病人除了可在診所進行植入式心臟儀器檢查外，遙距監察 (Remote Monitoring) 也成為一種趨勢。遙距監察利用電話或數據網絡，上載病人儀器檢查的資料至雲端系統，再由心臟科主任醫生及護士以密碼登入查看病人的紀錄。上傳的數據包括儀器運作檢查和心律不整紀錄，較先進的儀器更能顯示肺水腫指標以反映心臟衰竭情況，這些資料都用以輔助醫生進行心臟疾病管理。

葛量洪醫院為香港首間發展遙距監察系統的醫院，當初引入系統是由於醫院接收的心臟衰竭病人情況較嚴峻，我們希望更緊密關注他們的心臟健康。我們的監察團隊於二零零九年開始籌備，在二零一零年成立，而參加了遙距監察的病人現已逾百個。團隊的成員至今有十一人，分別為三名心臟科醫生及八名心臟科護士或技術員，他們事前均需接受不同儀器公司及其監察系統的訓練。

我們日常工作主要是訊息檢查，訊息一般分為：儀器自動傳送(圖一)和病人主動傳送(圖二、三)。



(圖一) 心臟科護士及醫生定期檢查病人心臟儀器的報告傳送，包括特別警報。有任何警報，心臟科護士會先與病人確認，再報告醫生，然後對病人作出適當指引或治療。



(圖二) 病人感到不適，主動致電監察小組並傳送心臟儀器資料。



(圖三) 心臟科護士接收儀器資料，分析情況，並向醫生作出匯報，醫生會根據資料作適當安排和治療。

遙距監察系統不經不覺在醫院已運行了三年多，開始時監察團隊和病人實在需要一段時間協調及適應。然而，當系統發展成熟後，好處亦慢慢顯現。最令我感到窩心的是，整個團隊與病人關係更加密切，每次對話都有著關懷慰問。我們會不厭其煩地提醒病人要注意的事項，病人因此逐漸熟悉心臟健康轉壞的病徵，提高自己對病情的關注。此外，由於儀器警報系統可以立時通知醫護人員有關病人的心臟情況，這大大增加病人接受及時治理的機會，舒緩病情，以免情況惡化。對於病情較穩定的病人，也可減少到門診覆診的次數，避免舟車勞頓。

縱使香港地方小，交通亦四通八達，但相信這個應用將會越來越普及，希望大家能善用科技，為未來的醫療服務帶來進步。

**注意：遙距監察系統並不能取代緊急醫療服務，有緊急狀況請即求診!**

# Thank You!